Introducing novel AD biomarkers into clinical practice: how close are we?

The field of biomarkers for Alzheimer’s disease (AD) has grown rapidly in recent years, particularly with novel blood-based biomarkers such as phosphorylated tau181 (p-tau181) and p-tau217. Marta Milà-Alomà, PhD, Northern California Institute for Research and Education (NCIRE), San Francisco, CA, provides her perspective on the remaining challenges to be overcome before novel biomarkers can be introduced into clinical practice. Namely, she suggests that further research is needed to understand individual bioavailability and that procedures involving biomarkers would need to be standardized. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.